ArticleBMJ (Clinical research ed.)2019

EMA and FDA decisions based on flawed evidence to approve new cancer drugs negatively affect Latin American patients.

Carlos E Durán et al.PubMed ↗Publisher ↗

No numbers read from the abstract.